NASDAQ:ABUS - Arbutus Biopharma Stock Price, Price Target & More

$5.45 +0.05 (+0.93 %)
(As of 04/22/2018 12:19 PM ET)
Previous Close$5.45
Today's Range$5.25 - $5.50
52-Week Range$3.20 - $8.25
Volume110,929 shs
Average Volume166,314 shs
Market Capitalization$300.13 million
P/E Ratio-3.04
Dividend YieldN/A
Beta1.06

About Arbutus Biopharma (NASDAQ:ABUS)

Arbutus Biopharma logoArbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in Canada and the United States. It also develops a pipeline of products based on RNA interference therapeutics (RNAi). The company's lead candidate is ARB-1467, which is in a Phase II trial to block production of HBV surface antigen expression in patients chronically infected with HBV. Its product candidates also include AB-423, a core protein inhibitor in Phase I clinical trial as an oral therapeutic for the treatment of chronic HBV infection; and AB-452, an HBV RNA Destabilizer, which is in preclinical study. In addition, the company has various research programs for the discovery and development of proprietary HBV candidates comprising N-Acetylgalactosamine conjugate technology, cccDNA targeting agents, and checkpoint inhibition. Further, its partnered programs consist of Patisiran (ALN-TTR02), an RNAi therapeutic targeting transthyretin (TTR) that has been completed Phase III clinical trial for the treatment of TTR-mediated amyloidosis in patients with FAP; Marqibo for the treatment of adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in second or greater relapse or whose disease has progressed following two or more lines of anti-leukemia therapy; and RNA-based neoantigen immunotherapy products. The company has strategic alliance, licensing, and research collaboration agreements with Acuitas Therapeutics Inc.; Spectrum Pharmaceuticals, Inc.; Marina Biotech Inc.; U.S. National Institutes of Health; and The Baruch S. Blumberg Institute and Drexel University. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Burnaby, Canada.

Receive ABUS News and Ratings via Email

Sign-up to receive the latest news and ratings for ABUS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ABUS
CUSIPN/A
Phone604-419-3200

Debt

Debt-to-Equity Ratio0.09%
Current Ratio8.85%
Quick Ratio8.85%

Price-To-Earnings

Trailing P/E Ratio-3.04
Forward P/E Ratio-3.21
P/E GrowthN/A

Sales & Book Value

Annual Sales$10.70 million
Price / Sales28.05
Cash FlowN/A
Price / CashN/A
Book Value$2.41 per share
Price / Book2.26

Profitability

EPS (Most Recent Fiscal Year)($1.79)
Net Income$-84,410,000.00
Net Margins-796.23%
Return on Equity-55.28%
Return on Assets-36.75%

Miscellaneous

Employees130
Outstanding Shares55,070,000

How to Become a New Pot Stock Millionaire

Arbutus Biopharma (NASDAQ:ABUS) Frequently Asked Questions

What is Arbutus Biopharma's stock symbol?

Arbutus Biopharma trades on the NASDAQ under the ticker symbol "ABUS."

How were Arbutus Biopharma's earnings last quarter?

Arbutus Biopharma (NASDAQ:ABUS) posted its quarterly earnings data on Wednesday, March, 14th. The biopharmaceutical company reported ($0.90) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.39) by $0.51. The biopharmaceutical company earned $2.50 million during the quarter, compared to analysts' expectations of $0.70 million. Arbutus Biopharma had a negative return on equity of 55.28% and a negative net margin of 796.23%. View Arbutus Biopharma's Earnings History.

When is Arbutus Biopharma's next earnings date?

Arbutus Biopharma is scheduled to release their next quarterly earnings announcement on Thursday, May, 3rd 2018. View Earnings Estimates for Arbutus Biopharma.

What price target have analysts set for ABUS?

6 brokerages have issued 1-year target prices for Arbutus Biopharma's stock. Their predictions range from $5.00 to $32.00. On average, they expect Arbutus Biopharma's stock price to reach $12.3750 in the next year. View Analyst Ratings for Arbutus Biopharma.

Who are some of Arbutus Biopharma's key competitors?

Who are Arbutus Biopharma's key executives?

Arbutus Biopharma's management team includes the folowing people:
  • Dr. Mark Joseph Murray, Chief Exec. Officer, Pres and Exec. Director (Age 69)
  • Dr. Peter Lutwyche Ph.D., Chief Technology Officer (Age 52)
  • Dr. Michael J. Sofia Ph.D., Chief Scientific Officer (Age 60)
  • Dr. Elizabeth Howard Ph.D., J.D., Exec. VP & Gen. Counsel (Age 64)
  • Mr. Koert VandenEnden C.A., CPA, Interim CFO & VP of Fin.

Has Arbutus Biopharma been receiving favorable news coverage?

Press coverage about ABUS stock has trended somewhat negative on Sunday, according to Accern Sentiment Analysis. The research firm ranks the sentiment of press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Arbutus Biopharma earned a daily sentiment score of -0.02 on Accern's scale. They also assigned news articles about the biopharmaceutical company an impact score of 46.38 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

How do I buy shares of Arbutus Biopharma?

Shares of ABUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Arbutus Biopharma's stock price today?

One share of ABUS stock can currently be purchased for approximately $5.45.

How big of a company is Arbutus Biopharma?

Arbutus Biopharma has a market capitalization of $300.13 million and generates $10.70 million in revenue each year. The biopharmaceutical company earns $-84,410,000.00 in net income (profit) each year or ($1.79) on an earnings per share basis. Arbutus Biopharma employs 130 workers across the globe.

How can I contact Arbutus Biopharma?

Arbutus Biopharma's mailing address is 100-8900 GLENLYON PARKWAY, BURNABY A1, V5J 5J8. The biopharmaceutical company can be reached via phone at 604-419-3200 or via email at [email protected]


MarketBeat Community Rating for Arbutus Biopharma (ABUS)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  266 (Vote Outperform)
Underperform Votes:  185 (Vote Underperform)
Total Votes:  451
MarketBeat's community ratings are surveys of what our community members think about Arbutus Biopharma and other stocks. Vote "Outperform" if you believe ABUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABUS will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Arbutus Biopharma (NASDAQ:ABUS) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
6 Wall Street analysts have issued ratings and price targets for Arbutus Biopharma in the last 12 months. Their average twelve-month price target is $12.3750, suggesting that the stock has a possible upside of 127.06%. The high price target for ABUS is $32.00 and the low price target for ABUS is $5.00. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.672.672.833.00
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $12.3750$12.3750$12.50$15.00
Price Target Upside: 127.06% upside135.71% upside140.38% upside98.68% upside

Arbutus Biopharma (NASDAQ:ABUS) Consensus Price Target History

Price Target History for Arbutus Biopharma (NASDAQ:ABUS)

Arbutus Biopharma (NASDAQ:ABUS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/19/2018Chardan CapitalInitiated CoverageBuy -> Buy$8.25HighView Rating Details
3/19/2018WedbushDowngradeOutperform -> Neutral$9.00 -> $6.00MediumView Rating Details
1/5/2018B. RileyInitiated CoverageBuy -> Buy$10.00MediumView Rating Details
11/7/2017Leerink SwannReiterated RatingMarket Perform$4.00 -> $5.00N/AView Rating Details
10/4/2017JMP SecuritiesReiterated RatingOutperform$12.00 -> $13.00HighView Rating Details
6/2/2017Ladenburg ThalmannInitiated CoverageBuy$32.00LowView Rating Details
1/9/2017Bloom BurtonUpgradeAccumulate -> BuyN/AView Rating Details
8/21/2016William BlairReiterated RatingOutperformN/AView Rating Details
(Data available from 4/22/2016 forward)

Earnings

Arbutus Biopharma (NASDAQ:ABUS) Earnings History and Estimates Chart

Earnings by Quarter for Arbutus Biopharma (NASDAQ:ABUS)

Arbutus Biopharma (NASDAQ:ABUS) Earnings Estimates

2018 EPS Consensus Estimate: ($1.59)
2019 EPS Consensus Estimate: ($1.71)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183($0.42)($0.32)($0.38)
Q2 20183($0.44)($0.33)($0.39)
Q3 20183($0.44)($0.34)($0.38)
Q4 20183($0.63)($0.34)($0.44)
Q1 20192($0.46)($0.38)($0.42)
Q2 20192($0.46)($0.36)($0.41)
Q3 20192($0.47)($0.32)($0.40)
Q4 20192($0.66)($0.31)($0.49)

Arbutus Biopharma (NASDAQ ABUS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/2/2018($0.38)N/AView Earnings Details
3/14/2018After Market($0.39)($0.90)$0.70 million$2.50 millionViewListenView Earnings Details
11/2/2017Q3 2017($0.38)($0.17)$0.79 million$6.90 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.35)($0.28)$0.68 million$1.00 millionViewN/AView Earnings Details
5/4/20173/31/2017($0.30)($0.34)$7.50 million$0.20 millionViewListenView Earnings Details
3/21/2017Q4 2016($0.38)($0.38)$0.76 million($0.20) millionViewN/AView Earnings Details
11/3/2016Q3 2016($0.53)($0.31)$0.44 million$0.70 millionViewN/AView Earnings Details
8/4/2016Q2 2016($0.35)($0.35)$0.99 million$0.30 millionViewN/AView Earnings Details
5/4/2016Q1 2016($0.37)($0.31)$1.25 million$0.60 millionViewN/AView Earnings Details
3/9/2016Q4 2015($0.39)$0.31$2.55 million$12.71 millionViewN/AView Earnings Details
11/5/2015Q3 2015($0.31)($0.42)$3.37 million$4.10 millionViewN/AView Earnings Details
8/5/2015Q2($0.25)($0.20)$3.77 million$3.40 millionViewN/AView Earnings Details
5/6/2015Q1 2015($0.39)($0.40)$3.55 million$4.70 millionViewN/AView Earnings Details
3/12/2015Q4 2014($0.32)($0.27)$6.12 million$4.40 millionViewN/AView Earnings Details
11/6/2014Q314($0.40)($0.39)$3.71 million$4.40 millionViewN/AView Earnings Details
8/14/2014Q214($0.13)($0.11)$3.72 million$1.80 millionViewN/AView Earnings Details
5/14/2014Q1 2014$0.40($0.22)$18.55 million$4.43 millionViewN/AView Earnings Details
3/6/2014Q4 2013($0.02)($0.07)$7.57 million$7.60 millionViewN/AView Earnings Details
12/18/2013Q3($0.07)($0.12)ViewN/AView Earnings Details
11/13/2013Q3 2013($0.03)($0.24)$7.50 million$2.91 millionViewN/AView Earnings Details
8/12/2013Q2 2013($0.24)($0.21)$2.50 million$2.82 millionViewN/AView Earnings Details
5/14/2013Q1 2013($0.14)($0.18)$3.00 million$2.16 millionViewN/AView Earnings Details
3/27/2013Q4 2012($0.07)($0.38)ViewN/AView Earnings Details
12/18/2012Q3 2012($0.07)($0.12)ViewN/AView Earnings Details
8/14/2012Q2 2012($0.16)($0.19)ViewN/AView Earnings Details
5/15/2012Q1 2012($0.17)($0.25)ViewN/AView Earnings Details
3/27/2012Q4 2011$0.20($0.16)ViewN/AView Earnings Details
11/8/2011Q3 2011($0.30)($0.12)ViewN/AView Earnings Details
8/11/2011Q2 2011($0.31)($0.35)ViewN/AView Earnings Details
5/11/2011Q1 2011($0.36)($0.31)ViewN/AView Earnings Details
3/17/2010Q4 2009($0.05)ViewN/AView Earnings Details
3/24/2009Q4 2008($0.06)ViewN/AView Earnings Details
11/13/2008Q3 2008($0.11)ViewN/AView Earnings Details
8/14/2008Q2 2008($0.14)ViewN/AView Earnings Details
5/14/2008Q1 2008($0.02)ViewN/AView Earnings Details
3/31/2008Q4 2007$0.01ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Arbutus Biopharma (NASDAQ:ABUS) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Arbutus Biopharma (NASDAQ ABUS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 6.90%
Institutional Ownership Percentage: 62.12%
Insider Trading History for Arbutus Biopharma (NASDAQ:ABUS)
Institutional Ownership by Quarter for Arbutus Biopharma (NASDAQ:ABUS)

Arbutus Biopharma (NASDAQ ABUS) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/3/2017Michael J SofiaInsiderSell10,000$8.00$80,000.00View SEC Filing  
8/15/2017Michael J SofiaInsiderSell30,000$3.70$111,000.001,563,403View SEC Filing  
8/24/2015Richard C Henriques JrDirectorBuy1,000$6.95$6,950.001,000View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Arbutus Biopharma (NASDAQ ABUS) News Headlines

Source:
DateHeadline
Arbutus Biopharma (ABUS) Downgraded by Zacks Investment ResearchArbutus Biopharma (ABUS) Downgraded by Zacks Investment Research
www.americanbankingnews.com - April 19 at 10:12 PM
BRIEF-Arbutus And Roivant Launch Genevant Sciences With Platform To Develop Broad Range Of RNA Therapeutics ...BRIEF-Arbutus And Roivant Launch Genevant Sciences With Platform To Develop Broad Range Of RNA Therapeutics ...
www.reuters.com - April 13 at 5:33 PM
Arbutus and Roivant Launch Genevant Sciences with Industry-Leading Platform to Develop Broad Range of RNA ...Arbutus and Roivant Launch Genevant Sciences with Industry-Leading Platform to Develop Broad Range of RNA ...
globenewswire.com - April 13 at 5:33 PM
Arbutus Presents Complementary Results From Preclinical Combination Studies of HBV Therapeutic Candidates at ...Arbutus Presents Complementary Results From Preclinical Combination Studies of HBV Therapeutic Candidates at ...
globenewswire.com - April 13 at 5:33 PM
Form 8-K Arbutus Biopharma Corp For: Apr 12Form 8-K Arbutus Biopharma Corp For: Apr 12
www.streetinsider.com - April 13 at 5:33 PM
Arbutus Presents Complementary Results From Preclinical Combination Studies of HBV Therapeutic Candidates at EASL 2018Arbutus Presents Complementary Results From Preclinical Combination Studies of HBV Therapeutic Candidates at EASL 2018
finance.yahoo.com - April 12 at 5:39 PM
Arbutus and Roivant Launch Genevant Sciences with Industry-Leading Platform to Develop Broad Range of RNA Therapeutics for Genetic DiseasesArbutus and Roivant Launch Genevant Sciences with Industry-Leading Platform to Develop Broad Range of RNA Therapeutics for Genetic Diseases
finance.yahoo.com - April 11 at 5:32 PM
Zacks: Brokerages Anticipate Arbutus Biopharma (ABUS) Will Announce Earnings of -$0.38 Per ShareZacks: Brokerages Anticipate Arbutus Biopharma (ABUS) Will Announce Earnings of -$0.38 Per Share
www.americanbankingnews.com - April 8 at 11:16 PM
Arbutus Biopharma (ABUS) Downgraded by ValuEngine to SellArbutus Biopharma (ABUS) Downgraded by ValuEngine to Sell
www.americanbankingnews.com - April 5 at 6:52 PM
Arbutus Biopharma (ABUS) Receives Average Recommendation of "Hold" from AnalystsArbutus Biopharma (ABUS) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - April 5 at 1:38 PM
Arbutus Biopharma (ABUS) Upgraded to Buy by ValuEngineArbutus Biopharma (ABUS) Upgraded to Buy by ValuEngine
www.americanbankingnews.com - April 3 at 8:13 PM
Arbutus Biopharma (ABUS) Stock Rating Lowered by ValuEngineArbutus Biopharma (ABUS) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - April 1 at 2:04 PM
Arbutus Biopharma (ABUS) Cut to Sell at Zacks Investment ResearchArbutus Biopharma (ABUS) Cut to Sell at Zacks Investment Research
www.americanbankingnews.com - March 30 at 9:28 PM
BidaskClub Upgrades Arbutus Biopharma (ABUS) to "Hold"BidaskClub Upgrades Arbutus Biopharma (ABUS) to "Hold"
www.americanbankingnews.com - March 30 at 6:15 PM
Arbutus to Present HBV Data at 2018 EASL Liver MeetingArbutus to Present HBV Data at 2018 EASL Liver Meeting
finance.yahoo.com - March 29 at 8:26 AM
Arbutus Biopharma (ABUS) Rating Increased to Sell at ValuEngineArbutus Biopharma (ABUS) Rating Increased to Sell at ValuEngine
www.americanbankingnews.com - March 25 at 9:16 PM
Arbutus Biopharma (ABUS) Rating Lowered to Sell at BidaskClubArbutus Biopharma (ABUS) Rating Lowered to Sell at BidaskClub
www.americanbankingnews.com - March 24 at 1:56 PM
 Analysts Expect Arbutus Biopharma (ABUS) to Announce -$0.38 Earnings Per Share Analysts Expect Arbutus Biopharma (ABUS) to Announce -$0.38 Earnings Per Share
www.americanbankingnews.com - March 22 at 11:08 PM
Arbutus Biopharma (ABUS) Upgraded to "Hold" by Zacks Investment ResearchArbutus Biopharma (ABUS) Upgraded to "Hold" by Zacks Investment Research
www.americanbankingnews.com - March 22 at 4:32 PM
Wedbush Weighs in on Arbutus Biopharmas Q1 2018 Earnings (ABUS)Wedbush Weighs in on Arbutus Biopharma's Q1 2018 Earnings (ABUS)
www.americanbankingnews.com - March 22 at 9:24 AM
Edited Transcript of ABUS earnings conference call or presentation 15-May-07 4:00pm GMTEdited Transcript of ABUS earnings conference call or presentation 15-May-07 4:00pm GMT
finance.yahoo.com - March 22 at 8:24 AM
Edited Transcript of ABUS earnings conference call or presentation 14-Aug-12 8:30pm GMTEdited Transcript of ABUS earnings conference call or presentation 14-Aug-12 8:30pm GMT
finance.yahoo.com - March 22 at 8:24 AM
Wedbush Downgrades Arbutus Biopharma (ABUS) to Neutral Citing limited Upside in 2018 - StreetInsider.comWedbush Downgrades Arbutus Biopharma (ABUS) to Neutral Citing limited Upside in 2018 - StreetInsider.com
www.streetinsider.com - March 20 at 8:27 AM
Wedbush softens view on Arbutus on extended timeline for HBV candidatesWedbush softens view on Arbutus on extended timeline for HBV candidates
seekingalpha.com - March 19 at 5:18 PM
Wedbush Projects Limited Upside For Arbutus Shares This Year, Moves To SidelinesWedbush Projects Limited Upside For Arbutus Shares This Year, Moves To Sidelines
finance.yahoo.com - March 19 at 5:18 PM
Arbutus Biopharma (ABUS) Earns Buy Rating from Analysts at Chardan CapitalArbutus Biopharma (ABUS) Earns Buy Rating from Analysts at Chardan Capital
www.americanbankingnews.com - March 19 at 11:12 AM
Wedbush Lowers Arbutus Biopharma (ABUS) to NeutralWedbush Lowers Arbutus Biopharma (ABUS) to Neutral
www.americanbankingnews.com - March 19 at 10:59 AM
Chardan Capital Markets Resumes Arbutus Biopharma (ABUS) at Buy - StreetInsider.comChardan Capital Markets Resumes Arbutus Biopharma (ABUS) at Buy - StreetInsider.com
www.streetinsider.com - March 19 at 8:22 AM
B. Riley Brokers Cut Earnings Estimates for Arbutus Biopharma (ABUS)B. Riley Brokers Cut Earnings Estimates for Arbutus Biopharma (ABUS)
www.americanbankingnews.com - March 19 at 2:15 AM
Brokers Set Expectations for Arbutus Biopharmas Q1 2018 Earnings (ABUS)Brokers Set Expectations for Arbutus Biopharma's Q1 2018 Earnings (ABUS)
www.americanbankingnews.com - March 19 at 2:14 AM
Brokers Offer Predictions for Arbutus Biopharma Corps Q1 2019 Earnings (ABUS)Brokers Offer Predictions for Arbutus Biopharma Corp's Q1 2019 Earnings (ABUS)
www.americanbankingnews.com - March 16 at 1:54 PM
Arbutus Biopharma Corp (ABUS) Expected to Post Q1 2019 Earnings of ($0.46) Per ShareArbutus Biopharma Corp (ABUS) Expected to Post Q1 2019 Earnings of ($0.46) Per Share
www.americanbankingnews.com - March 16 at 1:19 PM
Arbutus Biopharma (ABUS) Raised to Hold at ValuEngineArbutus Biopharma (ABUS) Raised to Hold at ValuEngine
www.americanbankingnews.com - March 16 at 12:48 AM
Arbutus Biopharma (ABUS) Posts Quarterly  Earnings Results, Misses Expectations By $0.51 EPSArbutus Biopharma (ABUS) Posts Quarterly Earnings Results, Misses Expectations By $0.51 EPS
www.americanbankingnews.com - March 15 at 11:56 AM
Arbutus Announces Corporate Update and Year-End 2017 Financial ... - GlobeNewswire (press release)Arbutus Announces Corporate Update and Year-End 2017 Financial ... - GlobeNewswire (press release)
globenewswire.com - March 15 at 8:15 AM
7 Stocks Moving In Wednesdays After-Hours Session | Benzinga - Benzinga7 Stocks Moving In Wednesday's After-Hours Session | Benzinga - Benzinga
www.benzinga.com - March 15 at 8:15 AM
Arbutus Announces Corporate Update and Year-End 2017 Financial ResultsArbutus Announces Corporate Update and Year-End 2017 Financial Results
finance.yahoo.com - March 14 at 7:08 PM
Arbutus Biopharma Corporation (NASDAQ:ABUS) Is Expected To BreakevenArbutus Biopharma Corporation (NASDAQ:ABUS) Is Expected To Breakeven
finance.yahoo.com - March 14 at 7:08 PM
Arbutus Announces Conference Call to Provide a Corporate Update and Fourth Quarter 2017 Year-End Financial Results - GlobeNewswire (press release)Arbutus Announces Conference Call to Provide a Corporate Update and Fourth Quarter 2017 Year-End Financial Results - GlobeNewswire (press release)
globenewswire.com - March 14 at 8:31 AM
Arbutus Announces Conference Call to Provide a Corporate Update and Fourth Quarter 2017 Year-End Financial ResultsArbutus Announces Conference Call to Provide a Corporate Update and Fourth Quarter 2017 Year-End Financial Results
finance.yahoo.com - March 12 at 9:01 AM
Arbutus Biopharma (ABUS) Set to Announce Quarterly Earnings on MondayArbutus Biopharma (ABUS) Set to Announce Quarterly Earnings on Monday
www.americanbankingnews.com - March 12 at 2:02 AM
Arbutus Biopharma Corp (ABUS) Given Average Recommendation of "Hold" by AnalystsArbutus Biopharma Corp (ABUS) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - March 11 at 4:02 PM
Arbutus Biopharma (ABUS) Upgraded to "Hold" at BidaskClubArbutus Biopharma (ABUS) Upgraded to "Hold" at BidaskClub
www.americanbankingnews.com - March 10 at 4:38 PM
Hudson Bay Capital Management LP Increases Stake in Arbutus Biopharma Corp (ABUS)Hudson Bay Capital Management LP Increases Stake in Arbutus Biopharma Corp (ABUS)
www.americanbankingnews.com - March 2 at 12:48 PM
K2 Principal Fund L.P. Purchases 11,311 Shares of Arbutus Biopharma Corp (ABUS)K2 Principal Fund L.P. Purchases 11,311 Shares of Arbutus Biopharma Corp (ABUS)
www.americanbankingnews.com - February 27 at 7:50 AM
Arbutus Biopharma (ABUS) Stock Rating Lowered by BidaskClubArbutus Biopharma (ABUS) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - February 24 at 3:52 PM
Arbutus Biopharma (ABUS) Settles Litigation with Acuitas Therapeutics - StreetInsider.comArbutus Biopharma (ABUS) Settles Litigation with Acuitas Therapeutics - StreetInsider.com
www.streetinsider.com - February 24 at 8:14 AM
Arbutus Biopharma (ABUS) Settles Litigation with Acuitas TherapeuticsArbutus Biopharma (ABUS) Settles Litigation with Acuitas Therapeutics
www.streetinsider.com - February 23 at 5:59 PM
Arbutus Settles Litigation, Terminating Acuitas Rights to LNP Technology - GlobeNewswire (press release)Arbutus Settles Litigation, Terminating Acuitas' Rights to LNP Technology - GlobeNewswire (press release)
www.globenewswire.com - February 23 at 8:21 AM
Arbutus Settles Litigation, Terminating Acuitas’ Rights to LNP TechnologyArbutus Settles Litigation, Terminating Acuitas’ Rights to LNP Technology
finance.yahoo.com - February 22 at 5:38 PM

SEC Filings

Arbutus Biopharma (NASDAQ:ABUS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Arbutus Biopharma (NASDAQ:ABUS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Arbutus Biopharma (NASDAQ ABUS) Stock Chart for Sunday, April, 22, 2018

Loading chart…

This page was last updated on 4/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.